Search hospitals > Texas > Dallas
Mary Crowley Cancer Research
Claim this profileDallas, Texas 75230
Global Leader in Cancer
Global Leader in Solid Tumors
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Lung Cancer
Conducts research for Ovarian Cancer
290 reported clinical trials
6 medical researchers
Summary
Mary Crowley Cancer Research is a medical facility located in Dallas, Texas. This center is recognized for care of Cancer, Solid Tumors, Non-Small Cell Lung Cancer, Lung Cancer, Ovarian Cancer and other specialties. Mary Crowley Cancer Research is involved with conducting 290 clinical trials across 196 conditions. There are 6 research doctors associated with this hospital, such as Minal Barve, MD, James Strauss, Douglas Orr, MD, and Reva Schneider.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
HER2 positive
2Solid Tumors
Global LeaderStage IV
Stage III
PD-L1 positive
Top PIs
Minal Barve, MDMary Crowley Cancer Research3 years of reported clinical research
Expert in Cancer
Expert in Solid Tumors
46 reported clinical trials
71 drugs studied
James StraussMary Crowley Cancer Research4 years of reported clinical research
Studies Cancer
Studies Solid Tumors
25 reported clinical trials
48 drugs studied
Douglas Orr, MDMary Crowley Cancer Research4 years of reported clinical research
Expert in Solid Tumors
Studies Cancer
17 reported clinical trials
31 drugs studied
Reva SchneiderMary Crowley Cancer Research3 years of reported clinical research
Studies Cancer
Studies Solid Tumors
9 reported clinical trials
11 drugs studied
Clinical Trials running at Mary Crowley Cancer Research
Solid Tumors
Breast Cancer
Cancer
Lung Cancer
Ovarian Cancer
Colorectal Cancer
Non-Small Cell Lung Cancer
Endometrial Cancer
Bladder Cancer
Breast cancer
Dabrafenib + Trametinib Access
for Cancer
This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have fulfilled the requirements for the primary objective, and who are judged by the investigator as benefiting from continued treatment in the parent study as judged by the Investigator at the completion of the parent study.
Recruiting3 awards Phase 42 criteria
T3011 + Pembrolizumab
for Solid Cancers
This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients with advanced or metastatic solid tumors.
Recruiting2 awards Phase 1 & 214 criteria
TJ033721
for Cancer
This trial is testing a new drug called TJ033721 to see if it is safe and effective for people with advanced or metastatic solid tumors. The study will look at how the drug behaves in the body and its potential side effects. The goal is to find out if this drug can help treat severe cancer cases.
Recruiting1 award Phase 1
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Mary Crowley Cancer Research?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.